<DOC>
	<DOC>NCT00313846</DOC>
	<brief_summary>The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) (5, 10 and 20) in comparison to placebo transdermal system in subjects with moderate to severe osteoarthritis pain of the hip and knee currently treated with oral opioids. The double-blind treatment intervention duration is 4 weeks during which time supplemental analgesic medication (acetaminophen) will be provided to all subjects in addition to study drug.</brief_summary>
	<brief_title>Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee</brief_title>
	<detailed_description>Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>clinical diagnosis of chronic osteoarthritis of the hip or knee for 1 year or longer. an average pain due to osteoarthritis of moderate, moderatelysevere, or severe for the 14 days prior to enrollment. ingest opioid analgesics on a daily basis. ingest &gt;2500 milligrams (mg) acetaminophen on a daily basis. require &lt;20 mg or &gt;80 mg of morphine (or opioid equivalents) per day for control of their osteoarthritis pain. Other protocolspecific exclusion/inclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Chronic pain</keyword>
	<keyword>opioid</keyword>
	<keyword>transdermal</keyword>
	<keyword>osteoarthritis</keyword>
</DOC>